GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells

BACKGROUND: Docetaxel is the first chemotherapy agent approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). The limited survival benefit associated with the quick emergence of resistance and systemic toxicity diminished its efficacy. JNK-mediated apoptosis is one of the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer
Main Authors: Karanika, Styliani, Karantanos, Theodoros, Kurosaka, Shinji, Wang, Jianxiang, Hirayama, Takahiro, Yang, Guang, Park, Sanghee, Golstov, Alexei A., Tanimoto, Ryuta, Li, Likun, Thompson, Timothy C.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4484888/
https://ncbi.nlm.nih.gov/pubmed/26084402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-015-0395-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados